The new diabetes inhalers: new tools for the clinician.

作者信息

Cefalu William T

机构信息

Division of Nutrition and Chronic Diseases, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.

出版信息

Curr Diab Rep. 2007 Jun;7(3):165-7. doi: 10.1007/s11892-007-0026-2.

DOI:10.1007/s11892-007-0026-2

PMID:17547832

Abstract

摘要

相似文献

The new diabetes inhalers: new tools for the clinician.

Curr Diab Rep. 2007 Jun;7(3):165-7. doi: 10.1007/s11892-007-0026-2.

Insulin inhalation (Aradigm Corporation). NN 1998.

Drugs R D. 1999 Aug;2(2):110-1. doi: 10.2165/00126839-199902020-00006.

[Inhaled insulin--the breakthrough in the treatment of diabetes?].

Pol Arch Med Wewn. 2006 Dec;116(6):1213-9.

When should a provider consider insulin human inhalation powder?

JAAPA. 2016 May;29(5):16-8. doi: 10.1097/01.JAA.0000482307.71186.01.

Years in the making: inhaled insulin has finally arrived.

S D Med. 2006 Jul;59(7):301-2.

Inhaled insulin product approved.

Am J Health Syst Pharm. 2014 Aug 1;71(15):1238. doi: 10.2146/news140052.

Inhaled insulin preferred.

Diabetes Forecast. 2005 Jan;58(1):96, 98.

Whither inhaled insulin?

Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):413. doi: 10.1038/ncpendmet0264.

Inhaled human insulin.

Nat Rev Drug Discov. 2006 May;5(5):371-2. doi: 10.1038/nrd2052.

Inhaled insulin for diabetes mellitus.

N Engl J Med. 2007 Feb 1;356(5):497-502. doi: 10.1056/NEJMct063533.

本文引用的文献

Glucagon and glucagon-like peptide receptors as drug targets.

Curr Pharm Des. 2006;12(14):1731-50. doi: 10.2174/138161206776873671.

Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:142-7. doi: 10.4158/EP.12.S1.142.

Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.

Diabetologia. 2006 May;49(5):891-9. doi: 10.1007/s00125-006-0161-3. Epub 2006 Feb 28.

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Diabetologia. 2006 Feb;49(2):253-60. doi: 10.1007/s00125-005-0107-1. Epub 2006 Jan 14.

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.

Ann Intern Med. 2005 Oct 18;143(8):549-58. doi: 10.7326/0003-4819-143-8-200510180-00005.

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.

Diabetes Care. 2005 Jul;28(7):1630-5. doi: 10.2337/diacare.28.7.1630.

Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.

Diabetes Care. 2005 May;28(5):1077-82. doi: 10.2337/diacare.28.5.1077.

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.

Diabetes Care. 2004 Nov;27(11):2622-7. doi: 10.2337/diacare.27.11.2622.

Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

Diabetes Care. 2004 Oct;27(10):2356-62. doi: 10.2337/diacare.27.10.2356.

Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.

Diabetes Care. 2004 Jun;27(6):1318-23. doi: 10.2337/diacare.27.6.1318.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验